This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Elekta Announces Strategic Partnership With McLaren Health Care To Improve Cancer Care In Michigan





ATLANTA, Dec. 18, 2013 /PRNewswire/ -- The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ® oncology information system throughout McLaren's cancer network. This partnership will enable McLaren to deploy MOSAIQ to centralize patient information across radiation oncology, particle therapy and medical oncology into a single user interface, accessible by multi-disciplinary teams across McLaren's multiple locations.

"By developing a long-term agreement with McLaren, Elekta reinforces its leadership in oncology information systems," explained Tomas Puusepp, President and CEO of Elekta. "Our collaboration with McLaren will further strengthen the integration of the entire cancer system to help improve patient care," Puusepp added.

The agreement entered today goes beyond MOSAIQ; it currently includes 15 Elekta linear accelerators, one Leksell Gamma Knife®, seven brachytherapy systems, and Monaco® treatment planning system to further drive improvements in quality and patient safety. The agreement will be booked in Elekta's second half of fiscal year 2013-14 and is valued at more than USD 50 million.

"At McLaren we are committed to delivering the best cancer care in the world. Today, McLaren is one of the largest oncology providers in the State of Michigan and one of the largest in the United States," said Philip A. Incarnati, President and Chief Executive Officer of McLaren Health Care. "We knew we needed a global leader to help us connect our facilities in a way that allows providers to function in a multi-disciplinary fashion. Elekta is that partner," he explained.

McLaren will move to replace its current linear accelerator fleet with Elekta Versa HD™, a single system that delivers high-volume conventional techniques in addition to advanced treatments that require precise targeting. Versa HD is equipped with the Agility™ 160-leaf multileaf collimator for high-speed, high-precision beam shaping to support extremely accurate tumor targeting and to maximize the preservation of healthy tissue.

"By choosing Elekta as our partner, we will be able to give our patients access to the most advanced technology for treating cancer," said Justin Klamerus, MD, MMM, Chief Quality Officer and lead for McLaren's community-based cancer programs. "The comprehensive solution provided by Elekta, along with McLaren's slated opening of the Proton Therapy Center in Flint, enables our cancer program to become one of the most advanced radiation oncology providers in the world," highlighted Klamerus. "We have spent 18 months exploring this partnership and we are confident that Elekta will help us transform cancer care for our patients. No mission is greater than this," he added.

For further information, please contact: Johan Andersson, Director, Investor Relations, Elekta ABTel: +46 702 100 451, e-mail: johan.andersson@elekta.comTime zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, ElektaTel: +1 770-670-2447, e-mail: michelle.joiner@elekta.comTime zone: ET: Eastern Time

About ElektaElekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO: EKTAB. Website: www.elekta.com.

About McLaren Health Care McLaren Health Care, a 501(c)3 nonprofit organization, is a large, clinically integrated health delivery system that includes 11 hospitals, ambulatory surgery centers, imaging centers, the state's only proton therapy center, the state's largest network of cancer centers and providers, an employed primary care physician network, assisted living facilities, commercial and Medicaid HMOs, home health care and hospice, durable medical equipment, retail pharmacy services, and a wholly-owned medical malpractice insurance company. McLaren's current cancer care delivery network has 16 locations, treating in excess of 12,000 of Michigan's 57,500 newly diagnosed cancer cases. McLaren's network includes an NCI-designated comprehensive cancer center. More information at www.mclaren.org.

SOURCE Elekta

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs